Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual-center study

Akita, Hirofumi; Takahashi, Hidenori; Eguchi, Hidetoshi; Asukai, Kei; Hasegawa, Shinichiro; Wada, Hiroshi; Iwagami, Yoshifumi; Yamada, Daisaku; Tomimaru, Yoshito; Noda, Takehiro; Gotoh, Kunihito; Kobayashi, Shogo; Doki, Yuichiro; Sakon, Masato

doi:https://doi.org/10.1002/ags3.12418

Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual-center study

Akita, Hirofumi; Takahashi, Hidenori; Eguchi, Hidetoshi et al.

Annals of Gastroenterological Surgery, 2020, 5(3), 381-389

アクセス数:3,151件（2025-10-24 09:23 集計）

固定URL: https://hdl.handle.net/11094/78282

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
ags_12418	pdf	なし	994 KB	204	2021.01.15

Creative Commons : 表示 - 非営利

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual-center study
著者	NRID 1000070528463 1000070528463 著者名 Akita, Hirofumi
	NRID 1000090601120 1000090601120 ORCID 0000-0003-4801-3540 0000-0003-4801-3540 researchmap permalink hdnr_tkhs hdnr_tkhs Scopus Author ID 7405468781 7405468781 著者名 Takahashi, Hidenori
	NRID 1000090542118 1000090542118 researchmap permalink abcdabcdabcd abcdabcdabcd Scopus Author ID 7101627772 7101627772 ORCID 0000-0002-2318-1129 0000-0002-2318-1129 著者名 Eguchi, Hidetoshi
	NRID 1000010749732 1000010749732 著者名 Asukai, Kei
	NRID 1000060621026 1000060621026 著者名 Hasegawa, Shinichiro
	NRID 1000000572554 1000000572554 著者名 Wada, Hiroshi
	NRID 1000060597441 1000060597441 researchmap permalink yiwagami yiwagami Scopus Author ID 35074034100 35074034100 著者名 Iwagami, Yoshifumi
	NRID 1000060571396 1000060571396 ORCID 0000-0002-6702-3800 0000-0002-6702-3800 researchmap permalink dyamada79222 dyamada79222 Scopus Author ID 37008067700 37008067700 著者名 Yamada, Daisaku
	NRID 1000070528570 1000070528570 researchmap permalink yoshitotomimaru yoshitotomimaru Scopus Author ID 10240341100 10240341100 著者名 Tomimaru, Yoshito
	NRID 1000050528594 1000050528594 researchmap permalink t-noda t-noda Scopus Author ID 12764559600 12764559600 ORCID 0000-0002-6768-5783 0000-0002-6768-5783 著者名 Noda, Takehiro
	NRID 1000010362716 1000010362716 著者名 Gotoh, Kunihito
	NRID 1000030452436 1000030452436 researchmap permalink 30452436 30452436 Scopus Author ID 7405376089 7405376089 ORCID 0000-0002-8828-1067 0000-0002-8828-1067 著者名 Kobayashi, Shogo
	NRID 1000020291445 1000020291445 researchmap permalink ydoki3251 ydoki3251 Scopus Author ID 7006390687 7006390687 著者名 Doki, Yuichiro
	NRID 1000040170659 1000040170659 著者名 Sakon, Masato
キーワード等	CA19-9
	chemoradiotherapy
	FDG-PET
	neoadjuvant
	pancreatic cancer
内容	kita, H, Takahashi, H, Eguchi, H, et al. Difference between carbohydrate antigen 19‐9 and fluorine‐18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual‐center study. Ann Gastroenterol Surg. 2020; 00: 1– 9. https://doi.org/10.1002/ags3.12418.
抄録	Background: An accurate evaluation of neoadjuvant treatment is important to maximize the prognostic benefit of this strategy in each individual patient. The main aim of the present study is to investigate the difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) in evaluating the response to neoadjuvant treatment for resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC) patients. Methods: Pancreatic ductal adenocarcinoma patients with positive standard uptake values (SUV) on FDG-PET before neoadjuvant chemoradiotherapy (NACRT) were enrolled (n = 141). In all patients, CA19-9 and FDG-PET were evaluated before the initiation of and after the completion of NACRT. The statuses of CA19-9 and FDG uptake alterations during NACRT were assessed in association with survival and tumor recurrence profiles. Results: A favorable response in each CA19-9 and FDG-PET was significantly related to better survival, respectively, than the unfavorable response (44.3% vs 19.5%, P <.001 and 45.8% vs 24.6%, P <.001). The status of CA19-9 was significantly associated with the incidence of distant recurrence whereas the status of FDG-PET was significantly associated with the incidence of local recurrence, and only patients with a favorable response in both CA19-9 and PET statuses showed a significantly better survival than the others (5-year survival: 56% vs 24%, P <.001), and those with unfavorable response in either of CA19-9 or PET status showed similar poor survival to those with unfavorable in both (P =.164). Conclusion: CA19-9 and PET evaluation provided oncologically different risk assessments in terms of tumor recurrence profile, and favorable response in both CA19-9 and FDG-PET were necessary to achieve prognostic benefit from NACRT.
出版者	Blackwell Publishing Ltd
収録物名	Annals of Gastroenterological Surgery
巻(号)	5(3)
ページ	381-389
刊行年月	2020
言語	英語
ハンドルURL	https://hdl.handle.net/11094/78282
eISSN	24750328
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1002/ags3.12418
アクセス権	open access
権利情報	© 2020 The Authors. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Annals of Gastroenterological Surgery. 2020, 5(3), p. 381-389
DC.title	Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual-center study
DC.creator	Akita, Hirofumi
	Takahashi, Hidenori
	Eguchi, Hidetoshi
	Asukai, Kei
	Hasegawa, Shinichiro
	Wada, Hiroshi
	Iwagami, Yoshifumi
	Yamada, Daisaku
	Tomimaru, Yoshito
	Noda, Takehiro
	Gotoh, Kunihito
	Kobayashi, Shogo
	Doki, Yuichiro
	Sakon, Masato
DC.publisher	Blackwell Publishing Ltd
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2020
DC.identifier	https://doi.org/10.1002/ags3.12418
DC.subject	CA19-9
	chemoradiotherapy
	FDG-PET
	neoadjuvant
	pancreatic cancer
DC.description	kita, H, Takahashi, H, Eguchi, H, et al. Difference between carbohydrate antigen 19‐9 and fluorine‐18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual‐center study. Ann Gastroenterol Surg. 2020; 00: 1– 9. https://doi.org/10.1002/ags3.12418.
DCTERMS.abstract	Background: An accurate evaluation of neoadjuvant treatment is important to maximize the prognostic benefit of this strategy in each individual patient. The main aim of the present study is to investigate the difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) in evaluating the response to neoadjuvant treatment for resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC) patients. Methods: Pancreatic ductal adenocarcinoma patients with positive standard uptake values (SUV) on FDG-PET before neoadjuvant chemoradiotherapy (NACRT) were enrolled (n = 141). In all patients, CA19-9 and FDG-PET were evaluated before the initiation of and after the completion of NACRT. The statuses of CA19-9 and FDG uptake alterations during NACRT were assessed in association with survival and tumor recurrence profiles. Results: A favorable response in each CA19-9 and FDG-PET was significantly related to better survival, respectively, than the unfavorable response (44.3% vs 19.5%, P <.001 and 45.8% vs 24.6%, P <.001). The status of CA19-9 was significantly associated with the incidence of distant recurrence whereas the status of FDG-PET was significantly associated with the incidence of local recurrence, and only patients with a favorable response in both CA19-9 and PET statuses showed a significantly better survival than the others (5-year survival: 56% vs 24%, P <.001), and those with unfavorable response in either of CA19-9 or PET status showed similar poor survival to those with unfavorable in both (P =.164). Conclusion: CA19-9 and PET evaluation provided oncologically different risk assessments in terms of tumor recurrence profile, and favorable response in both CA19-9 and FDG-PET were necessary to achieve prognostic benefit from NACRT.
DC.rights	© 2020 The Authors. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	78282
citation_title	Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual-center study
citation_author	Akita, Hirofumi
	Takahashi, Hidenori
	Eguchi, Hidetoshi
	Asukai, Kei
	Hasegawa, Shinichiro
	Wada, Hiroshi
	Iwagami, Yoshifumi
	Yamada, Daisaku
	Tomimaru, Yoshito
	Noda, Takehiro
	Gotoh, Kunihito
	Kobayashi, Shogo
	Doki, Yuichiro
	Sakon, Masato
citation_publisher	Blackwell Publishing Ltd
citation_language	英語
citation_date	2020
citation_journal_title	Annals of Gastroenterological Surgery
citation_volume	5
citation_issue	3
citation_firstpage	381
citation_lastpage	389
citation_doi	https://doi.org/10.1002/ags3.12418
citation_public_url	https://hdl.handle.net/11094/78282

Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual-center study

閲覧可能ファイル

論文情報

論文詳細を表示